Articles
Page 2 of 27
-
Citation: Molecular Neurodegeneration 2023 18:92
-
Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson’s disease in rodent brains
Alpha-synuclein (α-syn) aggregation into proteinaceous intraneuronal inclusions, called Lewy bodies (LBs), is the neuropathological hallmark of Parkinson’s disease (PD) and related synucleinopathies. However, ...
Citation: Molecular Neurodegeneration 2023 18:91 -
Alzheimer’s genes in microglia: a risk worth investigating
Despite expressing many key risk genes, the role of microglia in late-onset Alzheimer’s disease pathophysiology is somewhat ambiguous, with various phenotypes reported to be either harmful or protective. Herei...
Citation: Molecular Neurodegeneration 2023 18:90 -
Donald Lowell Price, M.D. In memoriam
Citation: Molecular Neurodegeneration 2023 18:88 -
Multi-modal proteomic characterization of lysosomal function and proteostasis in progranulin-deficient neurons
Progranulin (PGRN) is a lysosomal glycoprotein implicated in various neurodegenerative diseases, including frontotemporal dementia and neuronal ceroid lipofuscinosis. Over 70 mutations discovered in the GRN gene ...
Citation: Molecular Neurodegeneration 2023 18:87 -
Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia
This narrative review focuses on the role of cholesteryl ester transfer protein (CETP) and peripheral lipoproteins in the vascular contributions to cognitive impairment and dementia (VCID). Humans have a perip...
Citation: Molecular Neurodegeneration 2023 18:86 -
Altered plasma protein profiles in genetic FTD – a GENFI study
Plasma biomarkers reflecting the pathology of frontotemporal dementia would add significant value to clinical practice, to the design and implementation of treatment trials as well as our understanding of dise...
Citation: Molecular Neurodegeneration 2023 18:85 -
α-Synuclein serine129 phosphorylation – the physiology of pathology
Citation: Molecular Neurodegeneration 2023 18:84 -
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Mitochondrial dysfunction is strongly implicated in the etiology of idiopathic and genetic Parkinson’s disease (PD). However, strategies aimed at ameliorating mitochondrial dysfunction, including antioxidants,...
Citation: Molecular Neurodegeneration 2023 18:83 -
Simple model systems reveal conserved mechanisms of Alzheimer’s disease and related tauopathies
The lack of effective therapies that slow the progression of Alzheimer’s disease (AD) and related tauopathies highlights the need for a more comprehensive understanding of the fundamental cellular mechanisms u...
Citation: Molecular Neurodegeneration 2023 18:82 -
Correction: Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come
Citation: Molecular Neurodegeneration 2023 18:81 -
Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease
Peptides and their mimetics are increasingly recognised as drug-like molecules, particularly for intracellular protein-protein interactions too large for inhibition by small molecules, and inaccessible to larg...
Citation: Molecular Neurodegeneration 2023 18:80 -
Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders
DNA sensing is a pivotal component of the innate immune system that is responsible for detecting mislocalized DNA and triggering downstream inflammatory pathways. Among the DNA sensors, cyclic GMP-AMP synthase...
Citation: Molecular Neurodegeneration 2023 18:79 -
cGAS-STING triggers inflammaging-associated neurodegeneration
Citation: Molecular Neurodegeneration 2023 18:78 -
Genome-wide analyses identify NEAT1 as genetic modifier of age at onset of amyotrophic lateral sclerosis
Patients with amyotrophic lateral sclerosis (ALS) demonstrate great heterogeneity in the age at onset (AAO), which is closely related to the course of disease. However, most genetic studies focused on the risk...
Citation: Molecular Neurodegeneration 2023 18:77 -
Mechanisms of ARIA: is it time to focus on the unique immune environment of the neurovascular unit?
Citation: Molecular Neurodegeneration 2023 18:76 -
Regulation of cortical hyperexcitability in amyotrophic lateral sclerosis: focusing on glial mechanisms
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the loss of both upper and lower motor neurons, resulting in muscle weakness, atrophy, paralysis, and eventually...
Citation: Molecular Neurodegeneration 2023 18:75 -
Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come
Citation: Molecular Neurodegeneration 2023 18:74 -
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress
Cerebral amyloid angiopathy (CAA) is a devastating condition common in patients with Alzheimer’s disease but also observed in the general population. Vascular oxidative stress and neurovascular dysfunction hav...
Citation: Molecular Neurodegeneration 2023 18:73 -
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts
Citation: Molecular Neurodegeneration 2023 18:72 -
TDP-43 pathology is associated with increased tau burdens and seeding
Most Alzheimer’s Disease (AD) cases also exhibit limbic predominant age-related TDP-43 encephalopathy neuropathological changes (LATE-NC), besides amyloid-β plaques and neurofibrillary tangles (NFTs) containin...
Citation: Molecular Neurodegeneration 2023 18:71 -
A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer’s disease patients from controls
With the emergence of microglia-modulating therapies there is an urgent need for reliable biomarkers to evaluate microglial activation states.
Citation: Molecular Neurodegeneration 2023 18:70 -
Correction: Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology
Citation: Molecular Neurodegeneration 2023 18:69 -
The Q/R editing site of AMPA receptor GluA2 subunit acts as an epigenetic switch regulating dendritic spines, neurodegeneration and cognitive deficits in Alzheimer’s disease
RNA editing at the Q/R site of GluA2 occurs with ~99% efficiency in the healthy brain, so that the majority of AMPARs contain GluA2(R) instead of the exonically encoded GluA2(Q). Reduced Q/R site editing incre...
Citation: Molecular Neurodegeneration 2023 18:65 -
Astrocytes of the optic nerve exhibit a region-specific and temporally distinct response to elevated intraocular pressure
The optic nerve is an important tissue in glaucoma and the unmyelinated nerve head region remains an important site of many early neurodegenerative changes. In both humans and mice, astrocytes constitute the m...
Citation: Molecular Neurodegeneration 2023 18:68 -
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps
Pro-apoptotic BAX is a central mediator of retinal ganglion cell (RGC) death after optic nerve damage. BAX activation occurs in two stages including translocation of latent BAX to the mitochondrial outer membr...
Citation: Molecular Neurodegeneration 2023 18:67 -
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
Citation: Molecular Neurodegeneration 2023 18:66 -
Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium
Retinal ganglion cell (RGC) death in glaucoma and other optic neuropathies results in irreversible vision loss due to the mammalian central nervous system’s limited regenerative capacity. RGC repopulation is a...
Citation: Molecular Neurodegeneration 2023 18:64 -
The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus
The risk for dementia increases exponentially from the seventh decade of life. Identifying and understanding the biochemical changes that sensitize the ageing brain to neurodegeneration will provide new opport...
Citation: Molecular Neurodegeneration 2023 18:63 -
Regulation of the hippocampal translatome by Apoer2-ICD release
ApoE4, the most significant genetic risk factor for late-onset Alzheimer’s disease (AD), sequesters a pro-synaptogenic Reelin receptor, Apoer2, in the endosomal compartment and prevents its normal recycling. I...
Citation: Molecular Neurodegeneration 2023 18:62 -
Amyloid fibril proteomics of AD brains reveals modifiers of aggregation and toxicity
The accumulation of amyloid beta (Aβ) peptides in fibrils is prerequisite for Alzheimer’s disease (AD). Our understanding of the proteins that promote Aβ fibril formation and mediate neurotoxicity has been lim...
Citation: Molecular Neurodegeneration 2023 18:61 -
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
Plasma assays for the detection of Alzheimer’s disease neuropathological changes are receiving ever increasing interest. The concentration of plasma glial fibrillary acidic protein (GFAP) has been suggested as...
Citation: Molecular Neurodegeneration 2023 18:60 -
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer’s disease mice
Amyloid-related imaging abnormalities (ARIA) have been identified as the most common and serious adverse events resulting from pathological changes in the cerebral vasculature during several recent anti-amyloi...
Citation: Molecular Neurodegeneration 2023 18:59 -
Translation dysregulation in neurodegenerative diseases: a focus on ALS
RNA translation is tightly controlled in eukaryotic cells to regulate gene expression and maintain proteome homeostasis. RNA binding proteins, translation factors, and cell signaling pathways all modulate the ...
Citation: Molecular Neurodegeneration 2023 18:58 -
TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains
Inclusions of TAR DNA-binding protein 43 kDa (TDP-43) has been designated limbic-predominant, age-related TDP-43 encephalopathy (LATE), with or without co-occurrence of Alzheimer’s disease (AD). Approximately,...
Citation: Molecular Neurodegeneration 2023 18:57 -
Oleoylethanolamide facilitates PPARα and TFEB signaling and attenuates Aβ pathology in a mouse model of Alzheimer’s disease
Age is the strongest risk factor for the development of Alzheimer’s disease (AD). Besides the pathological hallmarks of β-amyloid (Aβ) plaques and neurofibrillary tangles, emerging evidence demonstrates a crit...
Citation: Molecular Neurodegeneration 2023 18:56 -
Current views on meningeal lymphatics and immunity in aging and Alzheimer’s disease
Alzheimer’s disease (AD) is an aging-related form of dementia associated with the accumulation of pathological aggregates of amyloid beta and neurofibrillary tangles in the brain. These phenomena are accompani...
Citation: Molecular Neurodegeneration 2023 18:55 -
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function
Mutations of the gene TMEM106B are risk factors for diverse neurodegenerative diseases. Previous understanding of the underlying mechanism focused on the impairment of lysosome biogenesis caused by TMEM106B loss-...
Citation: Molecular Neurodegeneration 2023 18:54 -
Specific detection of tau seeding activity in Alzheimer’s disease using rationally designed biosensor cells
The prion-like propagation of tau in neurodegenerative disorders implies that misfolded pathological tau can recruit the normal protein and template its aggregation. Here, we report the methods for the develop...
Citation: Molecular Neurodegeneration 2023 18:53 -
Valosin containing protein (VCP): initiator, modifier, and potential drug target for neurodegenerative diseases
The AAA+ ATPase valosin containing protein (VCP) is essential for cell and organ homeostasis, especially in cells of the nervous system. As part of a large network, VCP collaborates with many cofactors to ensure ...
Citation: Molecular Neurodegeneration 2023 18:52 -
VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson’s disease
Mutations in the vacuolar protein sorting 35 ortholog (VPS35) gene cause late-onset, autosomal dominant Parkinson’s disease (PD), with a single missense mutation (Asp620Asn, D620N) known to segregate with disease...
Citation: Molecular Neurodegeneration 2023 18:51 -
Optimizing detection of Alzheimer’s disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO
Disease-modifying drug use necessitates better Alzheimer disease (AD) detection. Mild cognitive impairment (MCI) leverages cognitive decline to identify the risk group; similarly, mild behavioral impairment (M...
Citation: Molecular Neurodegeneration 2023 18:50 -
Axonal energy metabolism, and the effects in aging and neurodegenerative diseases
Human studies consistently identify bioenergetic maladaptations in brains upon aging and neurodegenerative disorders of aging (NDAs), such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and...
Citation: Molecular Neurodegeneration 2023 18:49 -
Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer’s disease
Despite being twice as likely to get Alzheimer’s disease (AD), African Americans have been grossly underrepresented in AD research. While emerging evidence indicates that African Americans with AD have lower c...
Citation: Molecular Neurodegeneration 2023 18:48 -
ACSS2-dependent histone acetylation improves cognition in mouse model of Alzheimer’s disease
Nuclear acetyl-CoA pools govern histone acetylation that controls synaptic plasticity and contributes to cognitive deterioration in patients with Alzheimer’s disease (AD). Nuclear acetyl-CoA pools are generate...
Citation: Molecular Neurodegeneration 2023 18:47 -
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease
Vascular cognitive impairment and dementia (VCID) is commonly caused by vascular injuries in cerebral large and small vessels and is a key driver of age-related cognitive decline. Severe VCID includes post-str...
Citation: Molecular Neurodegeneration 2023 18:46 -
The gut microbiome regulates astrocyte reaction to Aβ amyloidosis through microglial dependent and independent mechanisms
Previous studies show that antibiotic-mediated (abx) alteration of the gut microbiome (GMB) results in a reduction of amyloid beta (Aβ) plaques and proinflammatory microglial phenotype in male APPPS1-21 mice. ...
Citation: Molecular Neurodegeneration 2023 18:45 -
Overexpression of human alpha-Synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Parkinson disease
Braak’s hypothesis states that sporadic Parkinson’s disease (PD) follows a specific progression of pathology from the peripheral to the central nervous system, and this progression can be monitored by detecti...
Citation: Molecular Neurodegeneration 2023 18:44 -
Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer’s disease
Stroke and late-onset Alzheimer’s disease (AD) are risk factors for each other; the comorbidity of these brain disorders in aging individuals represents a significant challenge in basic research and clinical p...
Citation: Molecular Neurodegeneration 2023 18:43 -
Anti-amyloid therapies for Alzheimer disease: finally, good news for patients
Citation: Molecular Neurodegeneration 2023 18:42
Follow
- ISSN: 1750-1326 (electronic)